Galera Therapeutics enrolls patients for pancreatic cancer trial of GC4419
Galera Therapeutics said that it has wrapped up enrollment of patients for its phase 1b/2a safety and anti-cancer efficacy clinical trial of the combination of avasopasem manganese (GC4419) with stereotactic body radiation therapy (SBRT) in patients having locally advanced pancreatic cancer (LAPC). The US biotech company said that its investigational, selective small molecule superoxide dismutase (SOD) […]